BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ErgoD2 Achieves Important Safety Milestone for Entia Biosciences


2/1/2012 9:09:45 AM

SHERWOOD, Ore., Feb. 1, 2012 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCBB:ERGO) (ENTIA) announced today that it has successfully completed an acute oral toxicity study (LD50) with its proprietary ErgoD2™ whole-food formulation. ErgoD2™ is a 100% USDA organic formulation from mushrooms that are enhanced with the Company's patent pending UV light technology and contain naturally high concentrations L-Ergothioneine and Ergocalciferol (vitamin D2). ENTIA currently uses this formulation in its Groh™ hair and nail nutritional supplement and in its new line of ErgoD2™ branded medical foods that it intends to offer to healthcare providers treating patients with anemia, diabetes, and potentially other serious conditions. In August, ENTIA announced it had entered into a research agreement with Dr. Jack Rogers, Ph.D., Associate Professor of Psychiatry and Neuroscience at Harvard Medical School and Director of the Neurochemistry Laboratory at Massachusetts General Hospital, to evaluate the therapeutic and prophylactic potential of ErgoD2™ as a dietary therapy or as a palliative therapy for Parkinson's disease patients. Successful completion of the LD50 is an important milestone for the commencement of human trials and ENTIA's medical foods launch.

Read at GlobeNewswire

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES